- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Apr 5, 2022
Politics, Policy & Law
April 4 Quick Takes: University of California continues CRISPR IP fight
Plus Protalix gains on Fabry data and updates from Alnylam, Curis, Gilead, BMS
BioCentury | Oct 7, 2021
Product Development
Fabry disease’s five-year prospects look up
Comparing the profiles of up-and-coming therapies for Fabry disease
BioCentury | Jun 13, 2019
Product Development
Why BioMarin took gene therapy manufacturing into its own hands
The factors behind BioMarin’s decision to build rather than buy a facility for manufacturing gene therapies.
BioCentury | Sep 1, 2018
Politics, Policy & Law
Back to School 2018: A pathway to Biopharma 3.0
Back to School 2018: How external disrupters will drive biopharma to new business model
BioCentury | May 20, 2017
Strategy
Henri: N of 1
How the late Genzyme CEO Henri Termeer created the Orphan drug industry
BioCentury | Mar 28, 2016
Strategy
Canbridge can-can
Why Aveo's AV-203 is leading Canbridge to venture outside Asia
Items per page:
1 - 10 of 288